Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Sep 23

PMID 36142914

Authors

Lorenzo Bertani

Affiliations

Soon will be listed here.

Abstract

Inflammatory bowel diseases (IBD) are chronic relapsing diseases of the gastrointestinal tract of unknown origin, resulting from an aberrant immune response to microbial and gut-specific antigens in genetically susceptible patients [...].

Citing Articles

Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's Disease.

Feagan B, Colombel J, Panaccione R, Schreiber S, Ferrante M, Kamikozuru K Gastro Hep Adv. 2025; 4(1):100544.

PMID: 39802486 PMC: 11720434. DOI: 10.1016/j.gastha.2024.08.022.

The resolvin D2 and omega-3 polyunsaturated fatty acid as a new possible therapeutic approach for inflammatory bowel diseases.

Chaim F, Pascoal L, de Castro M, Palma B, Rodrigues B, Fagundes J Sci Rep. 2024; 14(1):28698.

PMID: 39562789 PMC: 11576872. DOI: 10.1038/s41598-024-80051-8.

RIPK2: a promising target for cancer treatment.

You J, Wang Y, Chen H, Jin F Front Pharmacol. 2023; 14:1192970.

PMID: 37324457 PMC: 10266216. DOI: 10.3389/fphar.2023.1192970.

A Review of Ophthalmic Complications in Inflammatory Bowel Diseases.

Pytrus W, Akutko K, Pytrus T, Turno-Krecicka A J Clin Med. 2022; 11(24).

PMID: 36556071 PMC: 9781961. DOI: 10.3390/jcm11247457.

References

Buie M, Quan J, Windsor J, Coward S, Hansen T, King J . Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2022; 21(9):2211-2221. DOI: 10.1016/j.cgh.2022.06.030. View

Sandborn W, Feagan B, DHaens G, Wolf D, Jovanovic I, Hanauer S . Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021; 385(14):1280-1291. DOI: 10.1056/NEJMoa2033617. View

Atreya R, Neurath M . IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis. 2022; 16(Supplement_2):ii54-ii63. PMC: 9097672. DOI: 10.1093/ecco-jcc/jjac007. View

Zhang Y, Li Y . Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014; 20(1):91-9. PMC: 3886036. DOI: 10.3748/wjg.v20.i1.91. View

Qiu Y, Chen B, Mao R, Zhang S, He Y, Zeng Z . Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol. 2017; 52(5):535-554. DOI: 10.1007/s00535-017-1324-3. View

Bodini G, Demarzo M, Djahandideh A, Ziola S, Risso P, Bertani L . Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques. Eur J Gastroenterol Hepatol. 2021; 34(4):382-388. DOI: 10.1097/MEG.0000000000002261. View

Nielsen O, Ainsworth M . Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013; 369(8):754-62. DOI: 10.1056/NEJMct1209614. View

Pithadia A, Jain S . Treatment of inflammatory bowel disease (IBD). Pharmacol Rep. 2011; 63(3):629-42. DOI: 10.1016/s1734-1140(11)70575-8. View

Guo A, Ross C, Chande N, Gregor J, Ponich T, Khanna R . High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists. Sci Rep. 2022; 12(1):1185. PMC: 8786839. DOI: 10.1038/s41598-022-05208-9. View

10.

Bertani L, Blandizzi C, Mumolo M, Ceccarelli L, Albano E, Tapete G . Fecal Calprotectin Predicts Mucosal Healing in Patients With Ulcerative Colitis Treated With Biological Therapies: A Prospective Study. Clin Transl Gastroenterol. 2020; 11(5):e00174. PMC: 7263645. DOI: 10.14309/ctg.0000000000000174. View

11.

Bertani L, Fornai M, Fornili M, Antonioli L, Benvenuti L, Tapete G . Serum oncostatin M at baseline predicts mucosal healing in Crohn's disease patients treated with infliximab. Aliment Pharmacol Ther. 2020; 52(2):284-291. DOI: 10.1111/apt.15870. View

12.

Ben-Horin S, Kopylov U, Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):24-30. DOI: 10.1016/j.autrev.2013.06.002. View

13.

Bertani L, Antonioli L, Fornai M, Tapete G, Baiano Svizzero G, Marchi S . Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterol Dietol. 2019; 65(4):298-308. DOI: 10.23736/S1121-421X.19.02621-7. View

14.

Al-Bawardy B, Shivashankar R, Proctor D . Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol. 2021; 12:651415. PMC: 8080036. DOI: 10.3389/fphar.2021.651415. View

15.

Toskas A, Akbar A . IBD therapeutics: what is in the pipeline?. Frontline Gastroenterol. 2022; 13(e1):e35-e43. PMC: 9234727. DOI: 10.1136/flgastro-2022-102130. View

16.

Scribano M . Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. World J Gastroenterol. 2018; 24(23):2457-2467. PMC: 6010939. DOI: 10.3748/wjg.v24.i23.2457. View

17.

Atreya R, Neurath M, Siegmund B . Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF?. Front Med (Lausanne). 2020; 7:517. PMC: 7492550. DOI: 10.3389/fmed.2020.00517. View

18.

Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

19.

Thunberg J, Bjorkqvist O, Hedin C, Forss A, Soderman C, Bergemalm D . Ustekinumab treatment in ulcerative colitis: Real-world data from the Swedish inflammatory bowel disease quality register. United European Gastroenterol J. 2022; 10(7):631-639. PMC: 9486503. DOI: 10.1002/ueg2.12275. View

20.

Lucaciu L, Constantine-Cooke N, Plevris N, Siakavellas S, Derikx L, Jones G . Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2022; 14:17562848211064004. PMC: 8721385. DOI: 10.1177/17562848211064004. View